18 and older, any sex, with Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Feasibility as Measured by Number of Participants With EMR (Electronic Medical Record) Documentation of AdherencePrimary· 12 weeks
Feasibility as measured by documentation of adherence assessment made by provider.
Group
Value
95% CI
Behavioral Intervention
116
Acceptability as Measured by Provider SurveyPrimary· 12 weeks
Acceptability as measured by provider survey, score range 1-5, with a higher score indicating that the intervention was more acceptable.
Group
Value
95% CI
Lupus Clinic Providers
4.4
± 0.6
Percentage of Adherent Participants as Determined by Medication Possession Ratio (MPR)Secondary· Baseline, 12 weeks
Medication Possession Ratio (MPR) = days with medication/total days. This will be determined by pharmacy refill data and calculated for 3 months (90 days). An MPR \> or = 80% indicates adherence.
Baseline (prior to intervention)
Group
Value
95% CI
Behavioral Intervention
46
12 weeks (after intervention)
Group
Value
95% CI
Behavioral Intervention
55
Sponsor's own description
This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07377006 — Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer
· NA
· not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o
· NA
· withdrawn
NCT07282158 — Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
· NA
· recruiting
NCT06904391 — Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COA
· NA
· recruiting
Other recruiting trials for Systemic Lupus Erythematosus
Currently open trials in the same condition.
NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P
· Phase 1
· recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases
· EARLY_PHASE1
· recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
· EARLY_PHASE1
· recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
· Phase 1
· recruiting
NCT07371468 — A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
· Phase 1
· recruiting
Other Duke University trials
Trials by the same sponsor.
NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation
· NA
· not yet recruiting
NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment
· NA
· not yet recruiting
NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
· Phase 1
· not yet recruiting
NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study
· NA
· not yet recruiting
NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duke University
Last refreshed: 17 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03738826.